|By Marketwired .||
|March 18, 2014 08:24 PM EDT||
TORONTO, ONTARIO -- (Marketwired) -- 03/19/14 -- Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Company") announced that Dr. Aiping Young is leaving her position as President and Chief Operating Officer of Lorus, effective today. William G. Rice, Ph.D., Chairman of the Board and Chief Executive Officer of the Company, and the other members of the Company's Board of Directors, on behalf of Lorus, thank Dr. Young for her years of service to the Company and wish her well in her future endeavors. Dr. Young's responsibilities will be assumed by other members of senior management.
Lorus is a biopharmaceutical company targeting essential apoptosis pathways to deliver transformational cancer drugs. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used alone and in combination with other drugs to successfully treat specific forms of cancer. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR.
This press release may contain forward-looking statements within the meaning of Canadian and US securities laws. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release.
Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. Such statements may not prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
Jun. 30, 2015 03:59 PM EDT
Jun. 30, 2015 02:15 PM EDT Reads: 2,065
Jun. 30, 2015 01:56 PM EDT Reads: 409
Jun. 30, 2015 01:45 PM EDT Reads: 1,916
Jun. 30, 2015 01:45 PM EDT Reads: 1,795
Jun. 30, 2015 01:30 PM EDT Reads: 2,046
Jun. 30, 2015 01:15 PM EDT Reads: 2,001
Jun. 30, 2015 12:30 PM EDT Reads: 1,790
Jun. 30, 2015 10:30 AM EDT Reads: 1,848
Jun. 30, 2015 10:20 AM EDT Reads: 452
Jun. 30, 2015 10:15 AM EDT Reads: 778
Jun. 30, 2015 09:45 AM EDT Reads: 817
Jun. 30, 2015 09:15 AM EDT Reads: 792
SYS-CON Events announced today that JFrog, maker of Artifactory, the popular Binary Repository Manager, will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based in California, Israel and France, founded by longtime field-experts, JFrog, creator of Artifactory and Bintray, has provided the market with the first Binary Repository solution and a software distribution social platform.
Jun. 30, 2015 09:00 AM EDT Reads: 751
"We got started as search consultants. On the services side of the business we have help organizations save time and save money when they hit issues that everyone more or less hits when their data grows," noted Otis Gospodnetić, Founder of Sematext, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
Jun. 30, 2015 08:45 AM EDT Reads: 712